BriaCell CEO Discusses Clinical Results Of Its Breast Cancer Immunotherapy Treatment In An Audio Interview With SmallCapVoice.com
SmallCapVoice.com Inc. ("SCV") announces the availability of a new audio interview with Dr. Bill Williams, CEO of BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))))) (TSXV:BCT), to discuss the positive initial efficacy data of the Company's phase I/IIaa clinical study of Bria-IMT™ in combination with Incyte's retifanlimab in advanced breast cancer.
In a poster presentation at the Society for Immunotherapy of Cancer's (SITC) 37th annual meeting earlier this week, BriaCell reported disease control, tumor shrinkage and potential survival benefit among 70% of the 12 patients enrolled in its 2021-2022 group of advanced breast cancer patients. Speaking with SCV's Stuart Smith, Dr. Williams defines the gravity of advanced breast cancer and the value of this positive data for patients who have failed other therapies.
"We're treating patients with very advanced breast cancer," Dr. Williams says. "These are patients who have failed at least two prior therapies, but most of them have failed on the average of six to seven prior attempts of therapy for their metastatic breast cancer. These are very difficult-to-treat patients. Their life expectancy is very short; many of them would otherwise be going on hospice."
BriaCell is now in discussions with the FDA to advance to its pivotal study and move forward with the registration study along the path to FDA approval. "That, of course, is our ultimate goal," says Dr. Williams. "We want to make this promising therapy available to as many patients as possible."
The full interview can be heard at: https://www.smallcapvoice.com/november-interview-briacell-therapeutics-corp-bctx-2/.